Results 111 to 120 of about 16,077 (204)
ABSTRACT Background/Objectives Dupilumab is an anti‐interleukin (IL)‐4 receptor (IL‐4Rα) monoclonal antibody used to manage atopic dermatitis (AD). There is a paucity of real‐world Australian data for dupilumab in paediatric AD, especially regarding differences in clinical profiles between age groups.
Paul Sun Woo Kim +7 more
wiley +1 more source
Integrated Clinical Trial and Molecular Profiling Reveals Immune Drivers of Chronic Hand Eczema
This study performed an unbiased molecular profiling of CHE patients across diverse etiologies to identify shared pathogenic drivers and evaluate the impact of IL‐4Rα blockade via dupilumab over 16 weeks. CHE shows a mixed immune signature involving type 1, 2, and 3 pathways with features of atopic dermatitis and psoriasis.
Perrine Gery +25 more
wiley +1 more source
Abstract Purpose To investigate changes in choroidal and retinal thickness before and during myopia control treatment with orthokeratology lenses (OKL) in myopic children. Methods This was a sub‐study of CONTROL and CONTROL2 studies. The present study was a 2‐year, prospective, single‐group interventional study consisting of a 6‐month pre‐treatment ...
P. O. Hansen, F. Møller, T. M. Jakobsen
wiley +1 more source
Mapping IgG epitopes of the major birch allergen Bet v 1 identified patient‐derived, hypoallergenic peptides that did not trigger degranulation. These findings support a novel, safer approach for peptide‐based allergen immunotherapy that leverages naturally induced IgG specificities from allergic individuals. ABSTRACT Background Allergen immunotherapy (
Lara Šošić +10 more
wiley +1 more source
Background: Alteration of environmental factors and air pollution affects the trend of allergic diseases especially in cities such as Tehran. This study aimed to determine the prevalence of allergic rhinitis, conjunctivitis, atopic dermatitis and asthma ...
Raheleh SHOKOUHI SHOORMASTI +12 more
doaj
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang +18 more
wiley +1 more source
OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta +4 more
wiley +1 more source
Pathophysiology of Allergic Conjunctivitis [PDF]
openaire +2 more sources
The eye reacts to foreign substances through a variety of specific and non-specific defense mechanisms. Constantly exposed to a great variety of microorganisms, the eye is capable of protecting itself without altering its own structure and function. Its resistance relies upon anatomic and physiological properties of its external components (eyelids ...
B E, Del Río-Navarro +3 more
openaire +1 more source
Corneal tomographic and densitometric characteristics in children with allergic conjunctivitis: a comparative pentacam AXL study. [PDF]
Karakiraz A +6 more
europepmc +1 more source

